ct contains on a per 
serving basis.
    (Response) The preamble of the proposed rule explicitly stated that 
this specific sucralose formulation, for which the petitioner submitted 
plaque pH data, was not being included in our consideration and stated 
the reason for our decision. FDA believes that we correctly decided to 
exclude the sucralose formulation in question, but we agree that our 
comment applies only to that formulation, which was tested in the 
submitted studies, and not to the SPLEND